.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,748,611

« Back to Dashboard

Details for Patent: 8,748,611

Title:Processes for preparing morphinan-6-one products with low levels of alpha beta-unsaturated compounds
Abstract: The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of .alpha.,.beta.-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound.
Inventor(s): Buehler; Henry J. (St. Louis, MO), Dummitt; William E. (St. Louis, MO), Mannino; Anthony (Maryland Heights, MO), Aubuchon; Dennis C. (Arnold, MO), Gu; Hong (Oak Park, CA)
Assignee: Mallinckrodt LLC (Hazelwood, MO)
Filing Date:Nov 11, 2011
Application Number:13/294,546
Claims:1. A process for the preparation of a morphinan-6-one product, the process comprising: forming a reaction mixture comprising a morphinan-6-one compound and an .alpha.,.beta.-unsaturated ketone compound; treating the reaction mixture with a non-thiol sulfur-containing compound to reduce the concentration of the .alpha.,.beta.-unsaturated ketone compound in the reaction mixture; and recovering the morphinan-6-one compound to produce the morphinan-6-one product; wherein the morphinan-6-one compound corresponds to Formula (2): ##STR00025## the .alpha.,.beta.-unsaturated ketone compound corresponds to Formula (3): ##STR00026## X is --N(R.sub.17)-- or --N.sup.+(R.sub.17aR.sub.17b)--; R.sub.1 and R.sub.2 are independently selected from hydrogen, substituted and unsubstituted acyl, acyloxy, alkenyl, alkoxy, alkoxyaryl, alkyl, alkylamino, alkynyl, amino, aryl, arylalkoxy, carboalkoxy, carbonyl, carboxyalkenyl, carboxyalkyl, carboxyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylether, halo, haloalkoxy, haloalkyl, heteroaryl, heterocyclic, hydroxyalkyl, hydroxyl, or nitro; R.sub.3 is hydrogen, hydroxy, protected hydroxy, alkoxy, or acyloxy; R.sub.10 is hydrogen, hydroxy, protected hydroxy, halo, keto, tosyl, mesyl, or trifluoromesyl; R.sub.14 is hydrogen, hydroxy, or protected hydroxy; R.sub.17 is hydrogen, alkyl, cycloalkyl, alkylcarboxy, alkylenecycloalkyl, alkoxycarbonyl, allyl, alkenyl, acyl, aryl, formyl, formyl ester, formamide, benzyl, or an amino protecting group; R.sub.17a and R.sub.17b are independently selected from hydrogen, alkyl, alkenyl, allyl, cycloalkyl, aryl, or benzylyl, and the morphinan-6-one product comprises less than about 0.1% (by weight morphinan-6-one product) of the .alpha.,.beta.-unsaturated ketone compound.

2. The process as set forth in claim 1 wherein at least one of the following conditions are present: (i) the molar ratio of non-thiol sulfur-containing compound to morphinan-6-one compound in the reaction mixture is from about 0.5:1 to about 3.0:1; (ii) the reaction mixture is treated with the non-thiol sulfur-containing compound for at least about 1 hour; (iii) the reaction mixture is treated with the non-thiol sulfur-containing compound at a temperature greater than room temperature; or (iv) the morphinan-6-one compound is recovered from the reaction mixture without the use of an organic solvent.

3. A process for producing a morphinan-6-one product, the process comprising: forming a reaction mixture comprising an .alpha.,.beta.-unsaturated ketone compound; treating the reaction mixture with a non-thiol sulfur-containing compound to reduce the .alpha.,.beta.-unsaturated ketone to form a morphinan-6-one compound; and recovering the morphinan-6-one compound to form the morphinan-6-one product; wherein the morphinan-6-one compound corresponds to Formula (2): ##STR00027## the .alpha.,.beta.-unsaturated ketone compound corresponds to Formula (3): ##STR00028## X is --N(R.sub.17)-- or --N.sup.+(R.sub.17aR.sub.17b)--; R.sub.1 and R.sub.2 are independently selected from hydrogen, substituted and unsubstituted acyl, acyloxy, alkenyl, alkoxy, alkoxyaryl, alkyl, alkylamino, alkynyl, amino, aryl, arylalkoxy, carboalkoxy, carbonyl, carboxyalkenyl, carboxyalkyl, carboxyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, cycloalkylether, halo, haloalkoxy, haloalkyl, heteroaryl, heterocyclic, hydroxyalkyl, hydroxyl, or nitro; R.sub.3 is hydrogen, hydroxy, protected hydroxy, alkoxy, or acyloxy; R.sub.10 is hydrogen, hydroxy, protected hydroxy, halo, keto, tosyl, mesyl, or trifluoromesyl; R.sub.14 is hydrogen, hydroxy, or protected hydroxy; R.sub.17 is hydrogen, alkyl, cycloalkyl, alkylcarboxy, alkylenecycloalkyl, alkoxycarbonyl, allyl, alkenyl, acyl, aryl, formyl, formyl ester, formamide, benzyl, or an amino protecting group; and R.sub.17a and R.sub.17b are independently selected from hydrogen, alkyl, alkenyl, allyl, cycloalkyl, aryl, or benzylyl.

4. The process as set forth in claim 1 wherein the non-thiol sulfur-containing compound is a sulfur-containing nucleophile.

5. The process as set forth in claim 1 wherein the non-thiol sulfur-containing compound is a sulfur-containing inorganic acid or salt thereof.

6. The process as set forth in claim 5 wherein the non-thiol sulfur-containing inorganic acid is selected from the group consisting of hydrosulfuric acid (H.sub.2S); sulfurous acid (H.sub.2SO.sub.3); persulfuric acid (H.sub.2SO.sub.5); thiosulfurous acid (H.sub.2S.sub.2O.sub.2); dithionous acid (H.sub.2S.sub.2O.sub.4); disulfurous acid (H.sub.2S.sub.2O.sub.5); dithioic acid (H.sub.2S.sub.2O.sub.6); pyrosulfuric acid (H.sub.2S.sub.2O.sub.7); peroxydisulfuric acid (H.sub.2S.sub.2O.sub.8); trithionic acid (H.sub.2S.sub.3O.sub.6); tetrathionic acid (H.sub.2S.sub.4O.sub.6); pentathionic acid (H.sub.2S.sub.5O.sub.6); chlorosulfonic acid (HSO.sub.3Cl); furosulfonic acid (HSO.sub.3F); sulfamic acid (HSO.sub.3NH.sub.2); salts thereof; and combinations thereof.

7. The process as set forth in claim 5 wherein the salt is selected from the group consisting of alkali metal salts, alkaline earth metal salts, ammonium salt (NH.sub.4.sup.+), and quaternary ammonium salts.

8. The process as set forth in claim 1 wherein the reaction mixture further comprises a media material.

9. The process as set forth in claim 8 wherein the weight ratio of media material to morphinan-6-one compound in the reaction mixture is from about 1:1 to about 50:1.

10. The process as set forth in claim 8 wherein the media material is an aqueous media or an aqueous/organic solvent biphasic media.

11. The process as set forth in claim 10 wherein the aqueous media is water.

12. The process as set forth in claim 10 wherein the aqueous/organic solvent biphasic media further comprises a phase transfer catalyst.

13. The process as set forth in claim 12 wherein the phase transfer catalyst is a quaternary ammonium salt.

14. The process as set forth in claim 1 wherein the molar ratio of non-thiol sulfur-containing compound to morphinan-6-one compound in the reaction mixture of from about 0.5:1 to about 3.0:1.

15. The process as set forth in claim 1 wherein the treatment is carried out in an inert atmosphere.

16. The process as set forth in claim 1 wherein the treatment is carried out in ambient air.

17. The process as set forth in claim 1 wherein the treatment is carried out at a pressure of from about 0.5 atm to about 2.0 atm.

18. The process as set forth in claim 1 wherein the reaction mixture has a pH of from about 3 to about 9.

19. The process as set forth in claim 18 wherein the reaction mixture has a pH of from about 6 to about 9.

20. The process as set forth in claim 1 wherein the reaction mixture is treated with the non-thiol sulfur-containing compound for about 1 hour to about 18 hours.

21. The process as set forth in claim 1 wherein the reaction mixture is treated with the non-thiol sulfur-containing compound for about 1 hour to about 10 hours.

22. The process as set forth in claim 1 wherein the reaction mixture is treated with the non-thiol sulfur-containing compound for at least about 1 hour.

23. The process as set forth in claim 1 wherein the reaction mixture is treated with the non-thiol sulfur-containing compound for about 5 hours.

24. The process as set forth in claim 1 wherein the reaction mixture is treated with the non-thiol sulfur-containing compound at a temperature greater than room temperature.

25. The process as set forth in claim 1 wherein the reaction mixture is treated with the non-thiol sulfur-containing compound at a temperature of from about 30.degree. C. to about 70.degree. C.

26. The process as set forth in claim 1 wherein the morphinan-6-one product comprises less than about 0.01% (by weight morphinan-6-one product) of an .alpha.,.beta.-unsaturated ketone compound.

27. The process as set forth in claim 1 wherein the morphinan-6-one product comprises less than about 0.001% (by weight morphinan-6-one product) of an .alpha.,.beta.-unsaturated ketone compound.

28. The process as set forth in claim 1 wherein the morphinan-6-one product comprises no detectable amount of an .alpha.,.beta.-unsaturated ketone compound.

29. The process as set forth in claim 1 wherein the morphinan-6-one compound is recovered from the reaction mixture without the use of an organic solvent.

30. The process as set forth in claim 1 wherein after treatment of the reaction mixture with the non-thiol sulfur-containing compound a residual sulfur-containing species is substantially removed from the reaction mixture.

31. The process as set forth in claim 7 wherein the non-thiol sulfur-containing compound is selected from the group consisting of sodium sulfite, sodium bisulfite, sodium hydrosulfite, ammonium bisulfite.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc